The generic drug market ‘is at risk now’ from deflation, trade group says

An imbalance in supply and demand is the root cause of recent pain for companies like Mylan and Teva Pharmaceuticals, said Chip Davis, CEO of the Association for Accessible Medicines, the trade group for generic and biosimilar medicines. “[Analysts are] pointing...